Stockscreener 앱 받기
12.74
0.47%
0.06
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Therapeutics Inc (XTER:38I) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Intellia Therapeutics Inc (XTER:38I) Stock Today? - GuruFocus
Intellia Therapeutics Inc Stock Baskets | XTER:38I - GuruFocus
Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
John M. Leonard to sell 22,675 Intellia (NASDAQ: NTLA) shares - Stock Titan
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4%Time to Sell? - MarketBeat
Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7%Here's What Happened - MarketBeat
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative? - Sahm
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA|Intellia Therapeutics Inc|Price:11.910|Chg%:+0.080 - TradingKey
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Intellia (NTLA) Q2 2026 Earnings Call Transcript - The Globe and Mail
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Stock Short Interest Falls to 39.57% - Quiver Quantitative
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada - MarketBeat
(NTLA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Research Analysts Offer Predictions for NTLA FY2026 Earnings - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates - webull.com
Intellia Therapeutics Insider Buyers See Boost After Market Cap Rose US$168m - Moomoo
Equities Analysts Issue Forecasts for NTLA Q2 Earnings - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Issues Earnings Results - MarketBeat
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Wall Street Zen - MarketBeat
NTLA SWOT Analysis: Financial Resilience Amidst Clinical Advancements Revealed in 10-Q Filing - GuruFocus
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues - Yahoo Finance
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing - Stock Titan
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ) - Seeking Alpha
Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring Potential 127.65% Upside with CRISPR Innovations - DirectorsTalk Interviews
Will Intellia’s (NTLA) Narrowing Losses and Heavy R&D Spend Shift Its Risk Reward Narrative? - Yahoo Finance
Intellia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... By GuruFocus - Investing.com Canada
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside - tradingview.com
Intellia Therapeutics 2Q 2026: Revenue $7.7M, Net loss $106.6M, EPS $(0.80) — 10-Q Summary - TradingView
[10-Q] Intellia Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Intellia Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlig - GuruFocus
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance
Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Earnings call transcript: Intellia posts Q2 2026 revenue miss as shares slip premarket - Investing.com
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating - marketscreener.com
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates - Investing.com
INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30Earnings Summary - TradingView
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z - TradingView
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M - Moomoo
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics Q2 Operating Expenses U - moomoo.com
Intellia plans first-half 2027 U.S. launch if FDA approves hereditary angioedema treatment - Stock Titan
Dimensional Fund Advisors LP Increases Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
0.86%
0.31%
자본화:
|
볼륨(24시간):